search icon
  • Print
  • ShareThis
  • Text Size

RSS Feed Print Category View
Gilead's Sofosbuvir Gains FDA Panel Approval
tkim@idsociety.org
Posted: Monday, October 28, 2013 1:14 PM
Joined: 2/20/2013
Posts: 38


"There were no big surprises for Gilead's $11 billion hepatitis C drug sofosbuvir at today's FDA panel review. The therapy, which promises to help create an entirely new standard of care for the millions of people afflicted with the virus, won a clear endorsement from agency experts. And now it's likely headed for a near-term approval as the FDA formally considers the application."

To read more, please visit: http://www.fiercebiotech.com/story/gilead-sweeps-fda-panel-vote-pioneering-hep-c-drug-sofosbuvir/2013-10-25?utm_medium=nl&utm_source=internal
 

| HIVMA | Contact Us

© Copyright IDSA 2013 Infectious Diseases Society of America

Full Site Mobile Site